Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2010 - 2026)

Sarepta Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.17% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $45.1 million (up 15.86% YoY), while the FY2025 annual figure was $44.5 million, up 18.02% from the prior year.
• Depreciation & Amortization (CF) was $10.6 million for Q1 2026 at Sarepta Therapeutics, up from $5.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $18.4 million in Q3 2025 to a low of $5.3 million in Q4 2025.
• Historically, Depreciation & Amortization (CF) has averaged $10.5 million across 5 years, with a median of $10.6 million in 2026.
• Biggest YoY gain for Depreciation & Amortization (CF) was 88.15% in 2025; the steepest drop was 49.76% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $10.6 million in 2022, then gained by 7.76% to $11.4 million in 2023, then fell by 8.06% to $10.5 million in 2024, then slumped by 49.76% to $5.3 million in 2025, then surged by 101.68% to $10.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $10.6 million (Q1 2026), $5.3 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.